A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04119453 |
|
Recruitment Status :
Active, not recruiting
First Posted : October 8, 2019
Last Update Posted : March 13, 2023
|
Sponsor:
Elevar Therapeutics
Information provided by (Responsible Party):
Elevar Therapeutics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | June 30, 2023 |
| Estimated Study Completion Date : | February 1, 2024 |